Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
"Leucine-Rich Repeat Serine-Threonine Protein Kinase-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A serine/threonine protein kinase with GTPase activity that contains 12 LEUCINE-rich repeats in its central region and 7 WD repeats C-terminal to its kinase and GTPase domains. It localizes to TRANSPORT VESICLES; the OUTER MITOCHONDRIAL MEMBRANE; and the GOLGI APPARATUS. It functions in PROTEIN TRANSPORT; regulates neuron morphology in the central nervous system, and also functions in the trafficking of SYNAPTIC VESICLES. Mutations in the LRRK2 gene have been identified in autosomal dominant cases of PARKINSON DISEASE (PARK8).
| Descriptor ID |
D000071158
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.534 D12.776.637.750
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Leucine-Rich Repeat Serine-Threonine Protein Kinase-2".
Below are MeSH descriptors whose meaning is more specific than "Leucine-Rich Repeat Serine-Threonine Protein Kinase-2".
This graph shows the total number of publications written about "Leucine-Rich Repeat Serine-Threonine Protein Kinase-2" by people in this website by year, and whether "Leucine-Rich Repeat Serine-Threonine Protein Kinase-2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 2 | 2 |
| 2007 | 0 | 4 | 4 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 3 | 3 |
| 2011 | 0 | 1 | 1 |
| 2013 | 0 | 2 | 2 |
| 2015 | 0 | 1 | 1 |
| 2019 | 1 | 1 | 2 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Leucine-Rich Repeat Serine-Threonine Protein Kinase-2" by people in Profiles.
-
Parkinson's disease variant detection and disclosure: PD GENEration, a North American study. Brain. 2024 Aug 01; 147(8):2668-2679.
-
Non-cell autonomous mechanism of Parkinson's disease pathology caused by G2019S LRRK2 mutation in Ashkenazi Jewish patient: Single cell analysis. Brain Res. 2019 11 01; 1722:146342.
-
Parkinson's disease age at onset genome-wide association study: Defining heritability, genetic loci, and a-synuclein mechanisms. Mov Disord. 2019 06; 34(6):866-875.
-
Discovery of LRRK2 inhibitors using sequential in silico joint pharmacophore space (JPS) and ensemble docking. Bioorg Med Chem Lett. 2015 Jul 01; 25(13):2713-9.
-
Structural variation and the expanding genomic architecture of Parkinson disease. JAMA Neurol. 2013 Nov; 70(11):1355-6.
-
Diapocynin prevents early Parkinson's disease symptoms in the leucine-rich repeat kinase 2 (LRRK2R?44?G) transgenic mouse. Neurosci Lett. 2013 Aug 09; 549:57-62.
-
Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S. Biochemistry. 2013 Mar 12; 52(10):1725-36.
-
Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucine-rich repeat kinase 2 and the G2019S mutant. Biochemistry. 2011 Nov 01; 50(43):9399-408.
-
Development of a mechanism-based high-throughput screen assay for leucine-rich repeat kinase 2--discovery of LRRK2 inhibitors. Anal Biochem. 2010 Sep 15; 404(2):186-92.
-
Multiple LRRK2 variants modulate risk of Parkinson disease: a Chinese multicenter study. Hum Mutat. 2010 May; 31(5):561-8.